Pathological Gambling Remains an Invisible Epidemic in Psychiatry

In terms of prevalence, pathological gambling is comparable to schizophrenia and bipolar disorder, and in some populations even exceeds them. Yet the disorder continues to remain on the periphery of clinical attention. The primary reason for this paradox is both simple and discouraging: clinicians simply do not conduct routine screening for gambling addiction, while patients, burdened by shame, do not report the problem themselves.

Meanwhile, the consequences of pathological gambling extend far beyond personal tragedy, making it a genuine public health concern. Persistent, recurrent gambling behavior leads to deteriorating quality of life, reduced functioning, and elevated risks of bankruptcy, divorce, and criminal activity.

Who Is at Risk and When the Disorder Manifests

The typical onset occurs during adolescence or early adulthood, with men presenting earlier. Epidemiological data continue to identify male sex as the leading risk factor, although the problem is rising rapidly among women against the backdrop of widespread availability of lotteries, casinos, and online platforms. Among adolescents and young adults, the prevalence of the disorder is higher than in older age groups, and its course is characterized by alternating periods of abstinence and relapse.

A person suffering from problem gambling poses a risk not only to themselves but also to those around them, and the disorder can present in highly unexpected ways. For example, an individual may strike a pedestrian because they were playing a game on their phone instead of watching the road. This is one of the reasons why South Carolina enacted the Hands on the Wheel law.

Four Steps Toward Diagnosis

Identifying pathological gambling does not require complex equipment. The algorithm consists of several sequential steps:

• Ask direct questions about whether the individual feels a loss of control over gambling and whether they are preoccupied with thoughts about it.

• Assess the degree of impairment: impact on family, social relationships, financial situation, and professional functioning, as well as the level of subjective distress.

• Rule out the possibility that gambling behavior is a manifestation of bipolar disorder.

• Where necessary, use available self-report questionnaires and clinical screening instruments.

Three Competing Models and None Definitive

Behavioral Addiction and Parallels with Substance Use

The clinical criteria for gambling largely mirror those of substance use disorders: tolerance and withdrawal, repeated unsuccessful attempts to stop, craving prior to engagement in the behavior, and a “high” from the process itself. Epidemiology reinforces the connection: pathological gamblers frequently misuse alcohol and other substances. Neuroimaging studies document similarities in brain activity during gambling urges and cocaine cravings, while genetic data point to overlapping hereditary contributions. Nevertheless, the resemblance to addiction does not fully account for the nature of the disorder.

Obsessive-Compulsive Spectrum: Repetition Without Identity

Repetitive thoughts and ritualized behavior link gambling to OCD; however, the key distinction lies in the patient’s relationship to their own actions. Gambling is typically ego-syntonic: it is perceived as acceptable and even desirable. Compulsions in OCD, by contrast, are ego-dystonic and generate internal resistance. Neurobiologically, the pictures also diverge: in OCD, cortico-basal ganglia-thalamic circuits are activated upon symptom provocation, whereas in pathological gamblers their activity is, conversely, reduced.

Affective Spectrum: Depression as Consequence, Not Cause

Many gamblers report that the excitement temporarily alleviates negative emotional states, giving rise to the self-medication hypothesis. A link with subclinical mania or cyclothymia has also been discussed. However, depressive symptoms in gamblers frequently prove reactive — a response to debt, shame, and social losses. The degree of comorbidity with bipolar disorder is likely lower than previously assumed, making differential diagnosis particularly important.

Pharmacotherapy Without Official Approval

No medication has received FDA approval specifically for the treatment of pathological gambling. Any prescription is off-label in nature, and patients must be informed both of this status and of the existing evidence base.

Opioid Antagonists Have Yielded the Most Convincing Signals

Some researchers believe that, in the future, pharmacological approaches may become universal across different forms of gambling addiction, regardless of the specific type of gambling activity involved. The spectrum of problem gambling today is considerably broader than the classic slot machines and poker: it encompasses gambling-style video games, virtual betting, and digital versions of traditional land-based entertainment. Among the latter, sic bo — an Asian dice table game — is becoming increasingly prominent, rapidly gaining popularity in both land-based casinos and online platforms.

In examining the scale of this phenomenon, we reviewed several industry sources and, in particular, chose to click here on a sic bo review site to assess the degree of its market penetration. It emerged that the game has long moved beyond a niche Asian segment and become mainstream, meaning its growing accessibility is making its own contribution to the spread of problem gambling behavior. This further confirms that pharmacotherapy for gambling must account not only for symptom severity but also for the expanding diversity of gambling formats.

Naltrexone in a 12-week double-blind trial (89 participants, mean dose 188 mg/day) significantly outperformed placebo in reducing the frequency and intensity of cravings, with the greatest effect observed in patients with the most severe cravings. Nalmefene confirmed the trend in a 16-week multicenter trial (207 participants), demonstrating statistically significant improvement without the hepatotoxicity associated with Naltrexone. The mechanism is linked to modulation of dopaminergic transmission in the mesolimbic pathway and a “dampening” of cravings. Limitations include nausea, the risk of elevated liver enzymes with Naltrexone (particularly in combination with NSAIDs), and substantial participant dropout from trials.

Antidepressants: Promises That Have Yet to Become Guarantees

Results from studies of serotonin reuptake inhibitors (SRIs) are inconsistent. Sertraline in a 6-month trial did not outperform placebo. Fluvoxamine showed an advantage in one crossover trial, but in another no significant differences were found, amid a high placebo response (59%). Paroxetine demonstrated efficacy in an 8-week study; however, a large 16-week multicenter trial failed to replicate the result. Nevertheless, certain observations merit attention: effective doses proved higher than those used in treating depression, and improvement occurred even in patients without depressive or anxiety symptoms, suggesting an independent effect on serotonergic impulse regulation.

Lithium Has Found Its Niche in Patients with Bipolar Spectrum Disorders

In the only randomized double-blind trial, sustained-release Lithium carbonate in 40 gamblers with bipolar spectrum disorders reduced the severity of gambling-related thoughts and cravings compared with placebo over 10 weeks. However, no differences were recorded in amounts lost, number of episodes, or duration of gambling sessions. The data are limited to a single study with a narrow sample.

Without Screening, There Is No Treatment

Pathological gambling remains a disorder more often concealed than disclosed. Without active and targeted screening, it will continue to elude clinical attention. The choice of therapy requires consideration of comorbid addictions, affective disorders, and OCD-spectrum conditions, as well as an open conversation with the patient regarding the off-label status of prescribed medications and their tolerability.